ExploRNA Therapeutics and ?ukasiewicz - IChP Announce Strategic Partnership to Advance GMP Manufacturing of Next-Generation mRNA Cap Analogs

WARSAW, Poland, Sept. 22, 2026 /PRNewswire/ -- ExploRNA Therapeutics, a pioneering biotechnology company specializing in novel mRNA capping technologies, and the ?ukasiewicz Research Network – Industrial Chemistry Institute (?ukasiewicz - IChP) today announced a strategic partnership. The collaboration focuses on delivering ExploRNA's proprietary cap analogs—including its highly efficient AvantCap Q1 technology—in Good Manufacturing Practice (GMP) quality, securing an essential raw material supply for clinical-stage mRNA therapeutics and vaccines. As mRNA technology continues to revolutionize the biopharmaceutical landscape, the demand for high-quality, scalable components is growing rapidly. Co-transcriptional capping is a critical step in mRNA manufacturing, directly impacting the yield, quality, and translation efficiency of the final drug product. By partnering with ?ukasiewicz - IChP, an institution renowned for its advanced chemical synthesis and production scaling capabilities, ExploRNA ensures that its industry partners have access to the premium-grade cap analogs required to advance their clinical programs and commercial pipelines. "This collaboration with ?ukasiewicz - IChP marks a critical milestone in our growth trajectory. Securing a reliable, high-quality GMP manufacturing partner is an important development step for ExploRNA," stated Prof. Jacek Jemielity, CEO of ExploRNA Therapeutics. "This partnership not only validates the scalability of our synthesis processes but also ensures that our proprietary innovations can seamlessly transition from the laboratory to life-saving clinical applications." The production of GMP-grade materials is crucial for the ongoing advancement of ExploRNA's commercial strategy, allowing the company to support global biotech and pharmaceutical developers from early-stage research through to late-stage clinical trials and full-scale commercialization. About ExploRNA Therapeutics ExploRNA Therapeutics is a biotechnology company focused on developing state-of-the-art mRNA capping technologies and platform solutions. By innovating at the core of mRNA design, ExploRNA provides solutions that significantly enhance mRNA translational efficiency for next-generation genetic medicines. About ?ukasiewicz - IChP The ?ukasiewicz Research Network – Industrial Chemistry Institute is a leading Polish research and development center specializing in chemical synthesis, process engineering, and scaling up production for the pharmaceutical and advanced chemical industries. Media Contact: info@explorna.com Logo - https://mma.prnewswire.com/media/3009039/ExploRNA_logo_Logo.jpg View original content:https://www.prnewswire.co.uk/news-releases/explorna-therapeutics-and-ukasiewicz---ichp-announce-strategic-partnership-to-advance-gmp-manufacturing-of-next-generation-mrna-cap-analogs-302883857.html